Ultra-LEAF™ Purified anti-human IFN-γ Antibody

Product Details

Verified Reactivity

Human

Reported Reactivity

Chimpanzee, Baboon, Cynomolgus, Rhesus

Antibody Type

Monoclonal

Host Species

Mouse

Formulation

0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.

Endotoxin Level

Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.

Preparation

The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.

Concentration

The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.

Application

ELISA Capture - Quality tested
ICFC, IHC-F, WB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 1.0 - 4.0 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of IFN-γ recombinant protein ranging from 1000 to 8 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

ELISA^1,2,5 and ELISPOT^3,4 Capture: The Purified MD-1 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated 4S.B3 (Cat. No. 502504/502514) antibody as the detecting antibody and recombinant human IFN-γ (Cat. No. 570209) as the standard. The LEAF™ Purified antibody is suggested for ELISPOT capture. For ELISPOT capture applications, a concentration range of 0.5-2 µg/ml is recommended.
Neutralization¹: The LEAF™ Purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of human IFN-γ bioactivity (Cat. No. 507513).
Additional reported applications (for the relevant formats) include: Western blotting^1,2, intracellular staining for flow cytometry⁶, and immunohistochemical staining⁷ of paraformaldehyde-fixed, saponin-treated frozen tissue sections.
Note: For testing human IFN-γ in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430101 to 430106) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)

1. Van der Meide P, et al. 1985. J. Immuno. Meth. 79:293.
2. Yazdanbakhsh M, et al. 1993. Eur. J. Immuno. 23:3312.
3. Besouw N, et al. 1994. J. Med. Primatol. 23:42.
4. Van der Meide P, et al. 1995. J. Med. Primatol. 24:271.
5. Hilkens C, et al. 1996. J. Immunol. 156:1722.
6. Hamann D, et al. 1996. J. Immunol. 156:1387.
7. Wassenaar A, et al. 1995. Infect. Immunity. 63:2147.

RRID

AB_2810641 (BioLegend Cat. No. 507503)
AB_2810641 (BioLegend Cat. No. 507504)

Antigen Details

Structure

Cytokine; dimer; 20-25 kD (Mammalian)

Bioactivity

Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC

Cell Sources

CD8⁺ and CD4⁺ T cells, NK cells

Cell Targets

T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts

Receptors

IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)

Cell Type

Tregs

Biology Area

Cell Biology, Immunology, Neuroinflammation, Neuroscience

Molecular Family

Cytokines/Chemokines

Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation

Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2

Gene ID

3458 View all products for this Gene ID

UniProt

View information about IFN-gamma on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Active Protocols: Sandwich ELISA - Video
• Sandwich ELISA Protocol

Related Pages & Pathways

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Other Formats

Certificate of Analysis